

Neth Heart J (2024) 32:463  
<https://doi.org/10.1007/s12471-024-01910-7>



## Reply to ‘Cost-effectiveness of long term left ventricular assist devices’

Isabell Wiethoff · Birgit Goversen · Michelle Michels · Jolanda van der Velden · Mickaël Hiligsmann · Tom Kugener · Silvia Evers

Accepted: 3 October 2024 / Published online: 5 November 2024  
 © The Author(s) 2024

We appreciate the interest in our manuscript and the growing attention on cost-effectiveness research.

Van Hout et al. refer to our graphical abstract, which functions as a structural approach to summarize existing economic evaluations for inheritable cardiomyopathies published until April 2021. Thereby, we simply described each study’s conclusion on the cost-effectiveness of a given intervention without including any personal reflections. As the figure itself did indeed not assess each study’s generalizability and transferability, we highlighted the number of included studies per category and concluded, in the graphical abstract as well as in the main text, that more research is needed to guide decision-making [1].

With great interest we read the study by Lim et al. (2022) saying that LVAD therapy may be cost-effective in advanced heart failure patients, which falls beyond the scope of our review as it was published after April 2021 and did not specifically target cardiomyopathy patients [2]. In the future, updated versions of our

systematic review will be essential to capture emerging evidence and ensure the continued relevance of the findings.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

### References

1. Wiethoff I, Goversen B, Michels M, et al. A systematic literature review of economic evaluations and cost-of-illness studies of inherited cardiomyopathies. *Neth Heart J*. 2023;31:226–37.
2. Lim HS, Shaw S, Carter AW, et al. A clinical and costeffectiveness analysis of the HeartMate 3 left ventricular assist device for transplant-ineligible patients: A United Kingdom perspective. *J Heart Lung Transplant*. 2022;41:174–86.

I. Wiethoff (✉) · M. Hiligsmann · T. Kugener · S. Evers  
 Department of Health Services Research, Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands  
[i.wiethoff@maastrichtuniversity.nl](mailto:i.wiethoff@maastrichtuniversity.nl)

B. Goversen · J. van der Velden  
 Department of Physiology, Amsterdam UMC, Vrije Universiteit, Amsterdam Cardiovascular Sciences Institute, Amsterdam, The Netherlands

M. Michels  
 Department of Cardiology, Thorax Center, Cardiovascular Institute, Erasmus MC Rotterdam, Rotterdam, The Netherlands

S. Evers  
 Netherlands Institute of Mental Health and Addiction, Centre for Economic Evaluation, Trimbos Institute, Utrecht, The Netherlands

